We studied 82 patients with different types of epilepsy and 49 neurologically intact non-epileptic controls, and identified three different subpopulations of epilepsy patients bearing significantly elevated levels of autoantibodies to either GluR3B-peptide of glutamate/AMPA receptor subtype 3 (17/82; 21% of patients), or to a peptide of NR2A subunit of glutamate/NMDA receptors (15/82; 18%), or to double-stranded (ds) DNA, the hallmark of systemic lupus erythematosus (13/80; 16%). Most patients had only one antibody type, arguing against cross-reactivity. Nearly all anti-dsDNA Ab-positive patients did not harbor anti-nuclear autoantibodies. Most patients had no history of brain damage, febrile convulsions, early onset epilepsy, acute epilepsy or intractable seizures. We suggest to measure the 'autoimmune-fingerprints' of epilepsy patients for diagnostic and therapeutic purposes.
|Number of pages||12|
|State||Published - Jun 2005|
Bibliographical noteFunding Information:
The authors thank Prof. Zvi Vogel and Prof. Yadin Dudai of The Weizmann Institute of Science, and Prof. Dov Lichtenberg, Dean of the Sadder Faculty of Medicine, Tel-Aviv University, for their important support and their constructive attitude that enabled this study to be performed. We also thank warmly Prof. Olivier Dulac (Paris) for his valuable and incisive comments on our manuscript. Special gratitude and appreciation go to Prof. David Steinberg, head of the Department of Statistics and Operations Research at the School of Mathematical Sciences, Tel Aviv University, for his rigorous statistical analysis and for his didactic comments. This study was supported by grants to Dr. M. Levite from Volkswagen Stiftung and CURE (USA) citizens United for Research in Epilepsy Inc.
- Double-stranded DNA (dsDNA)
- Glutamate receptor